SeraNovo Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 15

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 3

SeraNovo General Information

Description

Developer of a drug formulation platform intended to improve oral bioavailability of poorly water-soluble small molecules. The company's platform is built around a new class of liquids that are neither aqueous nor lipid and have negligible toxicity, enabling medical companies to ensure that medication can be better absorbed by the patients.

Contact Information

Website
www.seranovo.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • J.H. Oortweg 21
  • 2333 CH Leiden
  • Netherlands
Primary Industry
Drug Delivery
Other Industries
Pharmaceuticals
Corporate Office
  • J.H. Oortweg 21
  • 2333 CH Leiden
  • Netherlands

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

SeraNovo Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Secondary Transaction - Private Completed Generating Revenue
5. Accelerator/Incubator 08-Nov-2021 Completed Generating Revenue
4. Accelerator/Incubator 22-Aug-2019 Completed Generating Revenue
3. Debt - General 14-Feb-2019 Completed Generating Revenue
2. Early Stage VC 01-Dec-2018 Completed Startup
1. Accelerator/Incubator Completed Startup
To view SeraNovo’s complete valuation and funding history, request access »

SeraNovo Patents

  • 7

    Total Documents Applications and Grants

  • Total Patents Families

  • 3

    Granted

  • Pending

  • Expiring in next 12 mo

SeraNovo Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3870227-A2 Deep eutectic solvent platform for oral pharmaceutical formulations Active 24-Oct-2018
EP-3870227-B1 Deep eutectic solvent platform for oral pharmaceutical formulations Active 24-Oct-2018
ES-2937632-T3 Deep eutectic solvent platform for oral pharmaceutical formulations Active 24-Oct-2018
US-20210379184-A1 Deep eutectic solvent platform for oral pharmaceutical formulations Inactive 24-Oct-2018
WO-2020085904-A2 Deep eutectic solvent platform for oral pharmaceutical formulations Inactive 24-Oct-2018 A61K47/10
To view SeraNovo’s complete patent history, request access »

SeraNovo Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

SeraNovo Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
LifeSciences@Work Accelerator/Incubator
EIT Health Accelerator/Incubator
PLNT. Accelerator/Incubator
To view SeraNovo’s complete investors history, request access »

Ready to get started?

Request a free trial

SeraNovo FAQs

  • When was SeraNovo founded?

    SeraNovo was founded in 2017.

  • Where is SeraNovo headquartered?

    SeraNovo is headquartered in Leiden, Netherlands.

  • What is the size of SeraNovo?

    SeraNovo has 15 total employees.

  • What industry is SeraNovo in?

    SeraNovo’s primary industry is Drug Delivery.

  • Is SeraNovo a private or public company?

    SeraNovo is a Private company.

  • What is SeraNovo’s current revenue?

    The current revenue for SeraNovo is .

  • How much funding has SeraNovo raised over time?

    SeraNovo has raised $341K.

  • Who are SeraNovo’s investors?

    LifeSciences@Work, EIT Health, and PLNT. have invested in SeraNovo.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process